Grail Inc
NASDAQ:GRAL

Watchlist Manager
Grail Inc Logo
Grail Inc
NASDAQ:GRAL
Watchlist
Price: 100.98 USD -3.56% Market Closed
Market Cap: 3.9B USD

Grail Inc
Cash Equivalents

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Grail Inc
Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Grail Inc
NASDAQ:GRAL
Cash Equivalents
$214.2m
CAGR 3-Years
-1%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Cash Equivalents
$5.6B
CAGR 3-Years
-22%
CAGR 5-Years
-7%
CAGR 10-Years
-5%
Gilead Sciences Inc
NASDAQ:GILD
Cash Equivalents
$9.4B
CAGR 3-Years
26%
CAGR 5-Years
-6%
CAGR 10-Years
-4%
Amgen Inc
NASDAQ:AMGN
Cash Equivalents
$9.4B
CAGR 3-Years
0%
CAGR 5-Years
1%
CAGR 10-Years
11%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash Equivalents
$6.3B
CAGR 3-Years
-12%
CAGR 5-Years
3%
CAGR 10-Years
24%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash Equivalents
$2.5B
CAGR 3-Years
-10%
CAGR 5-Years
10%
CAGR 10-Years
14%
No Stocks Found

Grail Inc
Glance View

Market Cap
3.7B USD
Industry
Biotechnology

Grail Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Menlo Park, California and currently employs 1,370 full-time employees. The company went IPO on 2024-06-12. GRAIL, Inc., formerly GRAIL, LLC, is a healthcare company, which is engaged in saving lives and shifting the paradigm in early cancer detection. The company is focused on alleviating the global burden of cancer by using next-generation sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its products include Galleri and Beyond. The Galleri test is a commercially available screening test for early detection of multiple types of cancer, which is termed multi-cancer early detection (MCED). Galleri screening test results can help guide next steps for a diagnosis of cancer by healthcare providers.

GRAL Intrinsic Value
26.42 USD
Overvaluation 74%
Intrinsic Value
Price

See Also

What is Grail Inc's Cash Equivalents?
Cash Equivalents
214.2m USD

Based on the financial report for Dec 31, 2024, Grail Inc's Cash Equivalents amounts to 214.2m USD.

What is Grail Inc's Cash Equivalents growth rate?
Cash Equivalents CAGR 3Y
-1%

Over the last year, the Cash Equivalents growth was 120%. The average annual Cash Equivalents growth rates for Grail Inc have been -1% over the past three years .

Back to Top